Prescribing a code of conduct to regulate the relationship between doctors and pharmaceutical companies is a “serious” matter, the Supreme Court observed on Thursday, after a petitioner said a particular drug manufacturer spent hundreds of crores in freebies to medical practitioners.
The lawyer representing Federation of Medical and Sales Representatives Association of India (FMRAI) cited what he said was a Central Board of Direct Taxes (CBDT) press release to contend that the manufacturer of Dolo 650, a popular fever drug, had spent ₹1,000 crore in freebies, although HT could not verify the claim.
At this, Justice Dhananjaya Y Chandrachud, who was on the bench with Justice AS Bopanna, said: “What you are saying is not music to our ears. This is exactly what I had when I got Covid. This is a serious issue.”